[{"orgOrder":0,"company":"ME Therapeutics","sponsor":"Nanovation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ME Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ME Therapeutics \/ Nanovation Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"ME Therapeutics \/ Nanovation Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by ME Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : The collaboration aims to enhance the precision and efficacy of mRNA therapeutics to develop potential new cancer therapies by leveraging the cutting-edge LNP technologies of NanoVation.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 20, 2024

                          Lead Product(s) : mRNA-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Nanovation Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank